Identification and Confirmation of routes to market and commercialisation of proven DRAI technology

在英国，有400万人患有失明，超过40万人登记为失明或部分视力。如果在正确的时间进行正确的治疗，许多病例是可以预防的。例如，高达98%的糖尿病引起的失明可以通过早期发现和治疗来预防。目前，确认初步评估的等待时间可能长达3个月，这一等待时间给患者带来了直接和持续的眼睛健康的固有风险。我们的技术有可能彻底改变专业人员进行眼睛测试的方式，并可能导致更早地发现、治疗和/或预防常见眼病，如糖尿病视网膜病变、青光眼、该项目将使我们不仅能够清楚地定义购买者和最终用户的成本，还可以让人们受益于NHS和更广泛的经济/社会，还将使我们能够确保我们的突破性技术无缝地集成到现有的眼睛保健生态系统中。

Four million people live with sight loss in the UK, and more than 400,000 are registered as blind or partially sighted. With the right treatment at the right time, many cases are preventable. As an example, up to 98% of sight loss resulting from diabetes can be prevented by early detection and treatment. At present, wait times to confirm an initial evaluation can be up to 3 months, with the inherent risk this wait time introduces to a patients immediate and ongoing eye health.Our technology has the potential to revolutionise the way professionals carry out eye tests and could lead to earlier detection, treatment and/or prevention of common eye diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration through a readily available eye test being partnered with our award-winning software solution.This project will allow us to clearly define not only the purchaser and end-user cost but also the people benefit to the NHS and to the wider economy/society and will also allow us to ensure our ground-breaking technology seamlessly integrates into the existing eye health care ecosystem.